Dr. Kirk Beebe is the Chief Scientific Officer at GeneCentric. Prior to joining GeneCentric, Dr. Beebe headed the translational science group that focused on pharmaceutical partnerships at Metabolon. He and his colleagues pioneered the analysis of large scale datasets to generate insights that enabled Pharmaceutical R&D and precision medicine. His team’s work led to a wide range of advances such as deeper understanding of drug resistance mechanisms and discovery of pathways that drive prognosis and response. Prior to Metabolon, he was a scientist at Talecris Biotherapeutics (formerly Bayer HealthCare), contributing to development of new pipeline products.  His passion for translational research and technology innovation was honed as a post-doctoral scientist and senior research associate at the Scripps Research Institute where he uncovered mechanistic links between genetic code fidelity and disease and, prior to that, as a PhD student at Ohio State University where he pioneered an innovative chemical biology approach to finding ligands for signaling proteins (an approach that paved the way for finding leads for untargetable proteins such as KRas). Dr. Beebe’s work has been published in top journals including Science and Nature and reprinted as a classic to celebrate the century of the Journal of Biological Chemistry.

Dr. Philippe Chemla is Chief Business Officer at GeneCentric. Prior to joining GeneCentric, Dr. Chemla served as President of Diabetic Health Inc., CEO and Director at Clinical Sensors, which he negotiated the acquisition, Chief Business Officer for the David H. Murdock Research Institute, which he restructured as a commercial CRO, Vice President of Business Development at Metabolon where he led strategic engagements, and Director of Commercial Development at Diosynth Biotechnology. Prior to Diosynth, he led programs on bioethanol, gene switches and natural products as Director of Business Development and Research at Syngenta and Novartis (USA and Switzerland). Dr. Chemla holds a PhD in Chemistry from the Louis Pasteur University and an MBA from the Duke University Fuqua School of Business.

Dr. James Davison serves as Senior Translational Genomics Scientist. He joined GeneCentric Therapeutics in 2020 after serving as a Senior Study Director for Population Health at Metabolon, Inc. His prior work includes collaborating and interpreting metabolomics projects with Key Opinion Leaders (KOLs) in academia and in pharmaceutical partnerships.  His work with these clients has spanned the biological sciences spectrum and have included studies in cancer biology, immunology, metabolic syndrome, intestinal biology, and many more. Prior to Metabolon, he served as a Research Director for a basic science research lab in the Department of Anesthesiology at Duke University Medical Center. He completed his Ph.D. in 2017 at the University of North Carolina, Chapel Hill where he analyzed and interpreted RNA-seq, DNAse-seq and ChIP-Seq (transcription factor and histone) datasets to understand how the intestinal microbiota mediate chromatin and transcriptional responses of intestinal epithelia.

Jeff Burdine serves as Sr. Director, Information Technology.  Mr. Burdine is responsible for creating and maintaining all IT infrastructure required to allow the GeneCentric team to perform their work.  He brings over 17 years of IT experience in the clinical research field. Prior to joining GeneCentric he was the Vice President of Information Technology at Clinical Research Management (now ICON GPHS) responsible for a portfolio of program management, IT design, implementation, validation, integration and, support services, supporting the infrastructure and technology for large CRO programs in multi-therapeutic areas. He also brings expertise in commercial software to improve both business intelligence and processes. Prior to this Mr. Burdine worked at Ockham Development Group (now Chiltern) serving as the Global Director of Information Services.   Mr. Burdine earned a BSBA in Management Information Systems from Bowling Green State University

Dr. Eisner serves as Senior Vice President of Clinical & Corporate Development at GeneCentric. Previously he was a co-founder of Innocrin Therapeutics and served as Vice President of Clinical Operations and Vice President of Medical and Scientific Affairs.  Prior to Innocrin, he served as Director of Product Development at Viamet Pharmaceuticals.  He also was a Principal at Cato BioVentures where he held senior management positions in several portfolio companies.  He also served as a Clinical Research Scientist at Insmed, Inc.  Dr. Eisner received his PhD from the University of Wisconsin – Madison in Endocrinology and Physiology and conducted clinical research at Northwestern University Medical School and Brigham and Women’s Hospital.

Dr. Felix Frueh is Founder and Executive Partner at Opus Three, a regulatory consulting organization located in San Diego. He also spent several years at the US Food and Drug Administration as Associate Director for Genomics and played a key role in the early development of policies involving companion diagnostics, biomarker qualification, and personalized medicine. Dr. Frueh is also Co-Founder and Chief Science Officer of Selva Therapeutics, a San Diego-based pharmaceutical company. He was Chief Scientific Officer at Human Longevity and was President of the Medco Research Institute, leading the pharmacy benefit manager’s clinical research initiatives in health economics and outcomes research. Dr. Frueh serves on the boards of several pharma and diagnostic companies. He is a Fellow of the American College of Clinical Pharmacology and held faculty positions at Georgetown University and at the University of North Carolina. He received his education at Stanford University and the University of Basel in Switzerland, where he graduated magna cum laude in biochemistry.

Dr. Guo serves as Senior Bioinformatics Scientist. He joined GeneCentric Therapeutics in 2019. His prior work includes pediatric cancer preclinical testing and epidemiology studies investigating associations between genomic variants and clinical phenotypes, including nicotine dependence, red blood cell hemolysis, and various blood indexes. At GeneCentric, he is responsible for statistical analyses and bioinformatics pipeline development. Dr. Guo received his PhD in Bioinformatics at the North Carolina State University in 2015.

Howard Kartstein is Director of Business Development at GeneCentric, helping our partners to translate the complexity of tumor biology and create predictive response signatures. Prior to joining GeneCentric, Howard was a charter member of the Owlstone Medical business team developing the emerging science of Breath Biopsy. He helped clinicians to identify Inherited Metabolic Disorders and resolve diagnostic odysseys at Metabolon Precision Medicine and before (re)joining Metabolon, he managed a five-person sales team for Eurofins Pharma Discovery and directed client interactions for companies using Second Genome’s microbiome profiling and analysis services. Howard developed Metabolon’s pharmaceutical and consumer health franchises and has worked in sales and marketing for product and service companies including Cerep, Genzyme, PerSeptive Diagnostics and Seragen. He received his degree in microbiology from the University of New Hampshire, his advisors including Richard Blakemore, William Chesbro, Denise Maratea, Tom Pistole and Robert Zsigray.

Dr. Lai-Goldman is a Co-Founder and Executive Chairperson of GeneCentric Therapeutics. She served as CEO and President from the company’s founding in 2011 through 2018.      Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pennsylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is board-certified in anatomic and clinical pathology.

Dr. Mayhew serves as Director of Bioinformatics at GeneCentric. He specializes in developing classifiers in cancer using high-dimensional genomics data. He joined the company in 2014 after completing post-doctoral training at Duke University where he built predictive models for several cancer types using clinical and gene expression data. His prior work includes studying associations between genomic variants and complex diseases, including cystic fibrosis and Parkinson’s. Dr. Mayhew received his Doctor of Public Health in Biostatistics at the University of North Carolina at Chapel Hill.

Dr. Milburn serves as CEO and President at GeneCentric, joining the company in 2018 as Chief Scientific Officer. Prior to joining GeneCentric, Dr. Milburn was the CSO at Metabolon since 2005, leading the development and growth of the company’s successful research and development organization. In addition to overseeing R&D, he played an integral role in establishing high value scientific and commercial partnerships. Prior to Metabolon, he served as Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals and Senior Vice President of Research at Plexxikon. He also held senior research positions at Structural Genomix (VP of Structural Biology); and GlaxoWellcome (Department Head of Structural Chemistry). Dr. Milburn has published over 100 peer-reviewed scientific articles and received his PhD in Biophysical Chemistry from the University of California at Berkeley and was a post-doctoral research fellow at Harvard Medical School.

Dr. Joel Parker is Director of the Lineberger Bioinformatics Core and Research Associate Professor of Genetics at UNC. His research is focused on methodological development and integrated analysis supporting high-throughput research activities. Joel’s work in this field began with a double major in biology and computer science from the University of Tennessee (1999), and then followed with an MS at Vanderbilt University (2002). He worked in the lab of Chuck Perou before moving into industry as a bioinformatics consultant first with Constella Group, then Expression Analysis, a genomics services startup. During this time he received his PhD at UNC (2010). Joel’s PhD work and continuing work with Nanostring resulted in Prosigna, the first FDA-approved IVDMIA with indications in breast cancer. Shortly after completing his PhD he returned to UNC to lead the Lineberger Bioinformatics Core. Under his leadership the core has grown to 20 employees, including eight PhDs in computational science.

Paul Armistead, MD, PhD is an Associate Professor of Medicine in the Division of Hematology at the University of North Carolina. Dr. Armistead was a Morehead Scholar at UNC, where he subsequently earned his MD, PhD. Dr. Armistead earned his PhD in Chemistry in the laboratory of Dr. Holden Thorp, former Chancellor of UNC, Provost of Washington University of St. Louis and current Editor-in-Chief of Science. He performed his Internal Medicine Residency at Brigham and Women’s Hospital and his Hematology / Oncology Fellowship at M.D. Anderson Cancer Center under the mentorship of Dr. Jeffrey Molldrem. Dr. Armistead is the Associate Chief of Hematology – Basic and Translational Research and the Medical Director of the UNC Advanced Cellular Therapeutics (GMP) Facility.

Chenyqua Shepard is the Chief Operating Officer.    Mrs. Shepard has over 30 years of experience in accounting and finance within various industries including pharmaceuticals, telecommunications, real estate, construction and retail/manufacturing and has more than 15 years in various leadership roles in the life sciences industry.  She has been responsible for various functions including technical accounting, financial and SEC reporting, financial planning and analysis, internal controls, information technology, human resources, and has been involved in several start-ups and emerging businesses.  Prior to joining GeneCentric, Mrs. Shepard was a partner with Rankin-McKenzie where she served several emerging companies as their part-time or interim Chief Financial Officer or Controller.  Prior to her partnership with Rankin-McKenzie Mrs. Shepard was the Chief Financial Officer of Praelia Pharmaceuticals and the Vice President of Finance and Chief Accounting Officer at Cornerstone Therapeutics, which was later acquired by Chiesi USA.  She began her experience in life sciences as a Director of Accounting and Finance with Biovail Pharmaceuticals, a Canadian pharmaceutical company, which later merged with Valeant Pharmaceuticals.  She has been licensed as a certified public accountant since 1991 and began her accounting career with Deloitte Touche in 1989.  She earned both her Bachelor of Science in Business Administration and Masters of Accountancy from the University of North Carolina at Chapel Hill.

Dr. Shibata serves as Senior Bioinformatics Scientist. He joined GeneCentric Therapeutics in 2017 after completing his post-doctoral training at the University of North Carolina at Chapel Hill where he combined various genome-wide sequencing and experimental molecular techniques to understand the epigenetic dynamics of meiosis and disease. At GeneCentric, he oversees research analysis pipeline design, implementation and assay development. Dr. Shibata received his PhD in Genetics and Genomics from Duke University.

Josh Uronis serves as Laboratory Director of GeneCentric Therapeutics.  In 2014, he completed post-doctoral training at the Duke University Institute for Genome Sciences and Policy where he utilized patient-derived human cancer explant models for the study of colorectal cancer and helped develop a six-class molecular model for subtyping colorectal cancers.  Prior to this, Josh completed post-doctoral training at the University of North Carolina at Chapel Hill (UNC-CH) Center for Gastrointestinal Biology and Disease (CGIBD).  There, he investigated the role of the intestinal microbiota in the development of colorectal cancer.  Josh’s research efforts resulted in significant contributions to the field of colorectal cancer research, including the publication of 11 research articles in addition to oral presentations at GI ASCO and the Digestive Disease Week (DDW) Annual Symposium.  Josh received his Ph.D. from UNC-CH in the Curriculum in Genetics and Molecular Biology.

Benjamin Vincent, MD is an Assistant Professor of Medicine, Division of Hematology at the University of North Carolina (UNC). Dr. Vincent was trained in cellular immunology and immunogenetics in the laboratory of Dr. Jeffrey Frelinger, former Chairman of the UNC Department of Microbiology/Immunology and past President of the American Association of Immunologists. He completed a research fellowship in the laboratory of Dr. Jonathan Serody, and he is currently a member of the Lineberger Comprehensive Cancer Center Immunotherapy Group, Faculty Director of the Immunogenomics Facility, and Leader of the MP1U Pre-clinical Immunotherapy Program.

Dr. Lai-Goldman is a Co-Founder and Executive Chairperson of GeneCentric Therapeutics. She served as CEO and President from the company’s founding in 2011 through 2018.      Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pennsylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is board-certified in anatomic and clinical pathology.

Dr. Levine has made significant contributions in the field of oncology in his research on the causes of cancer in both humans and animals. He was the first to discover the p53 tumour suppressor gene, which acts to protect individuals from developing cancer. Following his discovery, thousands of researchers have followed in Dr. Levine’s footsteps, seeking to focus on the p53 gene, which is the most commonly mutated gene in cancer.

Dr. Levine is currently a Professor at The Simons Center for Systems Biology at the Institute for Advanced Study in Princeton and a joint professor in the Pediatrics and Biochemistry Departments at the Cancer Institute of New Jersey. He received his PhD in microbiology from the University of Pennsylvania School of Medicine. Later he was a post-doctoral fellow of the Public Health Service at the California Institute of Technology.

Dr Levine also holds honorary degrees from, among other institutions, Rider University, the Weizmann Institute of Science, the University Pierre and Marie Curie in Paris and the University of Medicine and Dentistry of New Jersey. He has received many honours; most recently including the 2012 Onsager Medal, the Vallee Foundation Visiting Professorship, Harvard Medical School (2012), the Steven C. Beering Award for Advancement of Biomedical Science (2010), the American Cancer Society Medal of Honor (2009), the Kirk A. Landon-AACR Prize for Basic Cancer Research (2008), the Award for Basic Research from the Surgical Society of Oncologists (2003), the Albany Medical Center Prize in Medicine and Biomedical Research (2001), and the Medal for Outstanding Contributions to Biomedical Research from Memorial Sloan-Kettering Cancer Center (2000).

Ellen Lubman is a director of GeneCentric Therapeutics and currently Chief Business Officer at Werewolf Therapeutics.  She joined Werewolf from Impel NeuroPharma, where she was Chief Business Officer.  Prior to Impel, she was the Vice President of External Science & Innovation at Allergan, where, through two mergers from Forest Labs and Actavis, she was responsible for strategic expansion of the company’s diverse pipeline of therapeutics in a variety of disease areas. Ms. Lubman has held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank, and Abbott Labs. Ms. Lubman frequently advises emerging companies on business development strategy and fundraising. She serves on the Board of Directors of IntrepidaBio, as well as the Advisory Board of TMRW.org.  Ms. Lubman also currently serves on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell and Board of Directors of Gilda’s Club of NYC. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.

Dr. Milburn serves as CEO and President at GeneCentric, joining the company in 2018 as Chief Scientific Officer. Prior to joining GeneCentric, Dr. Milburn was the CSO at Metabolon since 2005, leading the development and growth of the company’s successful research and development organization. In addition to overseeing R&D, he played an integral role in establishing high value scientific and commercial partnerships. Prior to Metabolon, he served as Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals and Senior Vice President of Research at Plexxikon. He also held senior research positions at Structural Genomix (VP of Structural Biology); and GlaxoWellcome (Department Head of Structural Chemistry). Dr. Milburn has published over 100 peer-reviewed scientific articles and received his PhD in Biophysical Chemistry from the University of California at Berkeley and was a post-doctoral research fellow at Harvard Medical School.

The May Goldman Shaw Distinguished Professor of Molecular Oncology
Professor of Genetics, and of Pathology & Laboratory Medicine
Member of the Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Dr. Perou’s research crosses the disciplines of genomics, cancer biology, bioinformatics, epidemiology, and clinical trials. Among the numerous, transformational advances led by Dr. Perou has been in the characterization of the genomic diversity of breast tumors, which resulted in the discovery of the Basal-like/Triple-Negative Breast Cancer subtype. He and his colleagues demonstrated that breast cancers can be classified into at least five molecular subtypes, with his lab focusing particular attention on the Basal-like subtype.  He is also elucidating the genetic causes that give rise to each subtype, modeling these events in Genetically Engineered Mouse Models, and then using these models to investigate tumor biology and the efficacy of new drugs and new drug combinations.

Dr. Perou has authored more than 330 peer reviewed articles, and is an inventor on multiple USA and European patents. He is the Faculty Director of the Lineberger Comprehensive Cancer Center (LCCC) Bioinformatics Group, and Co-Director of the LCCC Breast Cancer Research Program. He is a member of the ALLIANCE/CALGB Breast Committee, and Co-Chair of the Triple-Negative Working Group of the Translational Breast Cancer Research Consortium. In order to fulfill the vision of bringing genomic assays into the everyday cancer clinic to make improvements in personalized patient care, Dr. Perou co-founded Bioclassifier LLC, in addition to GeneCentric Therapeutics, Inc.

Dr. Perou earned his BA in Biology from Bates College, his PhD in Cell Biology from the University of Utah and completed his postdoctoral work in David Botstein’s laboratory while at Stanford University.  He joined the faculty at UNC in 2000 and has received numerous awards since including the 2009 AACR Outstanding Investigator Award for Breast Cancer Research, the 2011 Danaher Scientific and Medical Award, the 2012 European Institute of Oncology Breast Cancer Therapy Award, the 2013 Hyman L. Battle Distinguished Cancer Research Award from UNC, the 2016 Jill Rose Award for Distinguished Biomedical Research from the Breast Cancer Research Foundation, and the 2016 Brinker Award for Scientific Distinction from the Susan G. Komen. Lastly he has been named a Thomson Reuters Most Highly Cited Researcher in Clinical Medicine for 2014-16.

Clay is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena and in 2000 co-founded Hatteras Venture Partners, a venture capital partnership that manages over $700 million across six vintages. Clay has led investments and numerous strategic transaction processes in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics, and research informatics. Some of these companies include: G1 Therapeutics (GTHX), Clearside Biomedical (Nasdaq: CLSD), Lysosomal Therapeutics, Inc., Asthmatx, Inc., PhaseBio Pharmaceuticals (PHAS), ArtusLabs, Embrella, Kymera Therapeutics (KYMR), and Synthematix, Inc.

Mr. Thorp currently serves as Chairman of PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS), and as a member of the board of directors of Clearside Biomedical, Inc. (NASDAQ: CLSD), StrideBio, Inc., Vigil Neuroscience, Inc., GeneCentric Therapeutics, Inc., and Seaport Diagnostics, Inc. He is also on the Strategic and Scientific Advisory Board of Brii Biosciences. Mr. Thorp serves on the Chancellor’s Philanthropic Committee at University of North Carolina (UNC) at Chapel Hill, the Board of Visitors of the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill and on the board of the North Carolina School of Science and Mathematics Foundation. He holds a Master of Public Policy (MPP) from Harvard University and a B.A. in mathematics and art history from UNC-Chapel Hill.

Scientific Director, University of Tennessee/West Institute for Cancer Research, and the Van Vleet Endowed Professor in Medical Oncology in the Department of Medicine (Division of Hematology‐Oncology).

Dr. Hayes’ research converges interests in multidisciplinary clinical care, clinical trials, translational cancer research, genomics, and model systems of cancer, with a focus on lung and head and neck cancers.  In the lab, he uses genetic and genomic techniques to characterize molecular alterations of cancer for the purposes of describing new patterns of clinically relevant disease and translating into includes biomarker discovery and validation.  Dr. Hayes currently is in his 10th year as a leader in efforts surrounding the Cancer Genome Atlas (TCGA), the pivotal genomic sequencing project of the decade.  His most notable accomplishments in this area include co‐leading the sequencing of RNA for most of the project, and playing a senior role in more than 20 manuscripts reported in Cell, Nature, and the New England Journal.

Early work by Dr. Hayes, performed in collaboration with his mentor Dr. Matthew Meyerson on human lung adenocarcinoma expression arrays from the National Cancer Institute revealed three reproducible molecular tumor subtypes of lung adenocarcinoma that are otherwise indistinguishable by routine clinical evaluation.  These subtypes possess statistically significant survival differences, independent of disease stage and are comprised of tumors with differing underlying rates of mutations in key lung cancer genes including KRAS and EGFR.  Similar findings for four subtypes of squamous cell carcinoma of the lung were also discovered and published.

Dr. Hayes most recently served as co‐leader of the University of North Carolina (UNC) Lineberger Clinical Research Program, professor in the Division of Hematology/Oncology and the Department of Otolaryngology/Head and Neck Cancer Surgery, and director of Clinical Bioinformatics at UNC.  Dr. Hayes lists more than 120 peer‐reviewed manuscripts in the last decade in the field of cancer research.  He received his BS from Davidson College, his MD from the University of North Carolina at Chapel Hill, his MPH from the Harvard School of Public Health and his MS from Tufts New England Medical Center. He completed his residency training in Internal Medicine at the Boston University School of Medicine, and additional fellowships in Hematology/Oncology at Tufts New England Medical Center and the Dana Farber Cancer Institute.

Hatteras Venture Partners is a venture capital firm that builds transformational companies in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. We typically invest in companies built on cutting-edge science from leading academic institutions. The firm has invested in companies across the United States in most of the major hotspots for health innovation. Given our headquarters location in RTP, NC, Hatteras plays a leadership role in building companies in North Carolina and the Southeastern United States, where technology is plentiful but resident venture capital is limited.

Learn More

Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.

Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.

Learn More

LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories.With scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, LabCorp processes tests on approximately 500,000 specimens each day, applying advances in medicine and science to laboratory testing.LabCorp operates a sophisticated laboratory network, with corporate headquarters in Burlington, NC, and more than 50,000 employees worldwide. Our 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. Laboratory Corporation of America Holdings is listed on the New York Stock Exchange (NYSE) under ticker symbol LH.

Learn More